<DOC>
	<DOC>NCT02724332</DOC>
	<brief_summary>To evaluate the clinical effect of rapamycin combined with TACE on early-stage HCC with overexpression of ASPH after radical surgery using randomized controlled study and provide a new anti-recurrence treatment for HCC patients after operation.</brief_summary>
	<brief_title>Adjuvant Anti-Recurrence Treatment With Rapamycin on Early-stage HCC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1. Via clinical diagnosis and confirm it is primary liver cancer 2. Pathological evidence of HCC 3. Estimate tumor can gain treatment of curing operation 4. No evidence for extrahepatic metestasis 5. liver function ：ChildPugh A/B 6. BCLC stage：0/1；TNM stage：Ⅰ 1. reject to attend； 2. impossible to come to our hospital for physical examination regularly. 3. cancer epitome、seed focus、lymph node or distant metastasis 4. Blood clotting function hindrance; 5, Patients with other diseases which may affect the treatment mentioned.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Aspartate beta hydroxylase</keyword>
	<keyword>transcatheter arterial chemoembolization</keyword>
</DOC>